Calidi biotherapeutics inc CLDI.US Overview Analysis
CLDI AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a low value rating. If your investment strategy is value-oriented and you have long-term positions, it's crucial to adhere to your exit plan and consider reducing holdings.
CLDI Current Performance
0.42%
Calidi biotherapeutics inc
-0.65%
Avg of Sector
0.16%
S&P500
Top 10 High Relevance to CLDI
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
GRAL | Grail inc | - | 4 | 2 | - | 1 | |
MNPR | Monopar therapeutics inc | 1 | 5 | 2 | 1 | 1 | |
MRVI | Maravai lifesciences holdings inc | 1 | 1 | 2 | 2 | 1 | |
DARE | Dare bioscience inc | 1 | 2 | 2 | 1 | 1 | |
VTYX | Ventyx biosciences inc | 2 | 2 | 2 | 1 | 1 |
- GRAL Grail incValue -Trend 4Swing Trading 2Whale Interest -Dividend 1See more
CLDI Profile
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.